This will take effect October 21, 2013
Overview and Clinical Utility:
Effective October 21, 2013, PathGroup will implement in-house testing for Beta-2-Microglobulin (B2M) Serum. B2M is a low molecular weight protein found on the surface of most nucleated cells. It forms the light chain component of the histocompatibility antigen and is eliminated via the kidneys. However, this is markedly increased in tubulo-interstitial disorders. Raised serum levels of B2M are associated with renal disease and rheumatoid arthritis. Elevated serum levels can also occur with systemic lupus erythematosus, malignant lymphoma and myeloma.
Click Here to read more.